Rapid Micro Biosystems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 07:00 am EDT
Share
Rapid Micro Biosystems, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 3.86 million compared to USD 6.13 million a year ago. Net loss was USD 13.09 million compared to USD 11.83 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 20.01 a year ago.
For the six months, revenue was USD 8.02 million compared to USD 11.13 million a year ago. Net loss was USD 28.02 million compared to USD 33.93 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 57.17 a year ago.
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
RAPID MICRO BIOSYSTEMS, INC. 
